Eli Lilly reported a historic 48% revenue growth in Q2 2026, driven by strong sales of Mounjaro and raised its full-year EPS guidance. Despite these results, the stock trades below its 52-week high due to concerns over U.S. price declines and acquisition charges. Analysts see modest upside, but a bullish valuation model suggests shares could reach $1,500 by late 2027 if key pipeline drugs like retatrutide succeed and regulatory approvals proceed smoothly. Risks include regulatory delays and pricing pressures on GLP-1 drugs, but the company’s strong growth and upcoming catalysts support potential multiple expansion and significant stock gains.
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
